Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Viruses

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    341 result(s) found for: Viruses. Displaying page 7 of 18.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2007-001828-12 Sponsor Protocol Number: 110221 Start Date*: 2007-05-07
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, open, non-randomized, multi-centric, single dose study to assess immunogenicity and safety of Fluarix™ (Influsplit SSW®) 2007/2008 injected intramuscularly in young adults (18 to 60 ye...
    Medical condition: Immunization against influenza of healthy adults
    Disease: Version SOC Term Classification Code Term Level
    9.1 10016794 Flu vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018341-56 Sponsor Protocol Number: VAC039 Start Date*: 2010-05-07
    Sponsor Name:University of Oxford
    Full Title: A phase I/IIa sporozoite challenge study to assess the safety, immunogenicity and protective efficacy of new malaria vaccine candidates; AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP...
    Medical condition: Malaria (plasmodium falciparum)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003192-22 Sponsor Protocol Number: M16-126 Start Date*: 2017-03-08
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Adults with Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection.
    Medical condition: Chronic hepatitis C virus genotype 5 or 6 infection, cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000074171 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003980-77 Sponsor Protocol Number: DEN-315 Start Date*: 2018-12-13
    Sponsor Name:Takeda Vaccines, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of Subcutaneous Administration of a Tetravalent Dengue Vaccine Candidate in Healthy Adoles...
    Medical condition: The purpose of this study is to describe the neutralizing antibody response against each dengue serotype at 1 month post second dose of TDV or placebo in dengue-naive adolescent participants.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10012312 Dengue fever virus infection LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-001927-39 Sponsor Protocol Number: ST1472-DM-03-007 Start Date*: 2005-01-20
    Sponsor Name:SIGMA-TAU
    Full Title: A PHASE II, MULTICENTER, UNCONTROLLED, OPEN STUDY IN PATIENTS WITH CHRONIC HEPATITIS C WHO ARE INTOLERANT TO INTERFERONS THERAPY TO EVALUATE THE SAFETY AND EFFICACY OF A TREATMENT WITH THYMOSIN ALP...
    Medical condition: TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C WHO ARE INTOLERANT TO INTERFERONS THERAPY
    Disease: Version SOC Term Classification Code Term Level
    6.1 10019744 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000279-40 Sponsor Protocol Number: SF3PEG-RIBA Start Date*: 2007-02-15
    Sponsor Name:A.S.L. 2
    Full Title: Randomised phase 3B study on comparison of 2 treatment schedules with peginterferon alpha 2b and ribavirin short term versus standard term schedules in patients with chronic hepatitis C, genotype...
    Medical condition: Patients with chronic hepatitis C with genotype 2 or 3
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001683-29 Sponsor Protocol Number: 114464 Start Date*: 2015-06-03
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase 2/3, randomized, controlled, observer-blind, multi-center trial to evaluate the safety and immunogenicity of a two-dose primary vaccination series of monovalent A/Indonesia/5/2005 (H5N1) va...
    Medical condition: Healthy volunteers (immunization against avian influenza virus A (H5N1) infection)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10073988 Bird flu LLT
    18.0 100000004865 10021433 Immunization LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-004971-30 Sponsor Protocol Number: FLUGEN-H3N2-V002 Start Date*: 2018-04-27
    Sponsor Name:FluGen, Inc
    Full Title: A Phase 2a Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Bris10 M2SR (H3N2 A/Brisbane/10/2007) Vaccine Administered as a Single Intranas...
    Medical condition: Prophylactic H3N2(A/Brisbane/10/2007) monovalent influenza vaccine, Bris10 M2SR, for protection against influenza disease caused by seasonal influenza A viruses.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022005 Influenza viral infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005679-18 Sponsor Protocol Number: GMX04 Start Date*: 2011-12-07
    Sponsor Name:Bio Products Laboratory Limited
    Full Title: A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents
    Medical condition: Primary immunodeficiency diseases
    Disease: Version SOC Term Classification Code Term Level
    14.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: Removed from public view
    EudraCT Number: 2015-001517-27 Sponsor Protocol Number: 208127/084,100566/567/568/569/570 Start Date*: 2015-06-03
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open multicentre, multicountry study to evaluate long-term anti-body persistence and immune memory between Years 11 and 15 after the primary study HAB-084 in which healthy adolescents were vacci...
    Medical condition: To protect healthy volunteers between the ages of 12 and 15 years against hepatitis A and hepatitis B viruses and to determine the optimal dose range and schedule of the combined hepatitis A / hepa...
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-003853-29 Sponsor Protocol Number: METVIRAL Start Date*: 2005-12-09
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: A randomized, controlled, multicenter clinical trial comparing the efficacy of Peginterferon alfa-2a and ribavirin and metformin versus Peginterferon alfa-2a and ribavirin for the treatment of naïv...
    Medical condition: CHRONIC ACTIVE HEPATITIS C ASSOCIATED WITH INSULIN RESISTANCE
    Disease: Version SOC Term Classification Code Term Level
    6.1 10019744 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018583-17 Sponsor Protocol Number: V71_19S Start Date*: 2010-05-17
    Sponsor Name:NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
    Full Title: A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2010-2011, when Administer...
    Medical condition: Influenza poses a significant threat to individual and public health, and influenza vaccination with a trivalent inactivated influenza vaccine is widely recommended to children, adults at risks and...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059430 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006588-21 Sponsor Protocol Number: HLS02/2006 Start Date*: 2007-05-10
    Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
    Full Title: Fluvastatin as adjuvant therapy to alfa-interferon and ribavirin in the treatment of chronic hepatitis C in patients with HIV-1 coinfection
    Medical condition: Chronic hepatitis C in HIV/HCV coinfection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000440-27 Sponsor Protocol Number: 690701 Start Date*: Information not available in EudraCT
    Sponsor Name:Baxter AG
    Full Title: OPEN-LABEL PHASE IV STUDY TO INVESTIGATE THE SEROPERSISTENCE OF TICK-BORNE ENCEPHALITIS (TBE) VIRUS ANTIBODIES AFTER THE FIRST BOOSTER AND THE RESPONSE TO A SECOND BOOSTER VACCINATION WITH FSME-IMM...
    Medical condition: In this Study the Seropersistence of Tick Borne Encephalitis (TBE) Virus Antibodies after the First Booster and the Response to a Second Booster Vaccination with FSME-IMMUN 0.5ml in Adults will be ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043847 Tick-borne viral encephalitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-011523-31 Sponsor Protocol Number: 09/H0720/64 Start Date*: 2009-06-23
    Sponsor Name:R & D, Cambridge University Hospitals
    Full Title: A study of the immune response to vaccination in MS patients treated with alemtuzumab
    Medical condition: The vaccinations are being used to investigate immunological memory following treatment of multiple sclerosis with the lympho-depleting humanised monoclonal antibody alemtuzumab.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis PT
    9.1 10063400 Secondary progressive multiple sclerosis PT
    9.1 10046859 Vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000337-36 Sponsor Protocol Number: FSJD-GLUCOBR-2010 Start Date*: 2011-08-30
    Sponsor Name:FUNDACIÓ SANT JOAN DE DÉU
    Full Title: IMPACT OF THE ADMINISTRATION OF SYSTEMIC GLUCOCORTICOIDS ON INFLAMMATORY RESPONSE AND CLINICAL EVOLUTION OF PATIENTS DIAGNOSED WITH MODERATE-SEVERE BRONCHIOLITIS
    Medical condition: Viral bronchiolitis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10038718 Respiratory syncytial virus bronchiolitis PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002352-24 Sponsor Protocol Number: Start Date*: 2016-08-02
    Sponsor Name:Imperial College Healthcare NHS Trust
    Full Title: Safety of Nasal Influenza Immunisation in Children with Asthma: The SNIFFLE 4 study
    Medical condition: Children aged 2-18 years (inclusive), with asthma / recurrent wheezing.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10001705 Allergic asthma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001275-23 Sponsor Protocol Number: OTL-101-5(17IC04) Start Date*: 2017-09-21
    Sponsor Name:Great Ormond Street Hospital for Children NHS Trust
    Full Title: Efficacy and safety of a cryopreserved formulation of autologous CD34+ haematopoietic stem cells transduced ex vivo with EFS lentiviral vector encoding for human ADA gene in subjects with Severe Co...
    Medical condition: Adenosine deaminase (ADA) deficiency is an inherited disorder that damages the immune system and causes severe combined immunodeficiency (SCID). Children with SCID lack virtually all immune protect...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10066372 ADA deficiency LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-000586-12 Sponsor Protocol Number: MATERIAL Start Date*: 2011-11-08
    Sponsor Name:Academic Medical Center
    Full Title: The efficacy of mepolizumab treatment on rhinovirus induced asthma exacerbations
    Medical condition: Asthma and more specifically virus-induced exacerbations in allergic asthma patients
    Disease: Version SOC Term Classification Code Term Level
    12.1 10015575 Exacerbation of asthma LLT
    12.1 10001705 Allergic asthma LLT
    12.1 10049868 Asthma exacerbation prophylaxis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006221-27 Sponsor Protocol Number: 146/2007/U/Sper Start Date*: 2008-04-01
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Immunosuppression without calcineurin inhibitors and with the use of everolimus (Certican) in HCV-infected liver transplant patients
    Medical condition: HCV cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 17:30:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA